Drugs.com - New Drug Approvals

FDA Approves Stoboclo (denosumab-bmwo), a Biosimilar to Prolia

JERSEY CITY, N.J., March 3, 2025 /PRNewswire/ -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Stoboclo (CT-P41, denosumab-bmwo), a biosimilar referencing Prolia (denosumab), for all indications of the...

Mar 5, 2025 - 02:25
 0
FDA Approves Stoboclo (denosumab-bmwo), a Biosimilar to Prolia
JERSEY CITY, N.J., March 3, 2025 /PRNewswire/ -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved Stoboclo (CT-P41, denosumab-bmwo), a biosimilar referencing Prolia (denosumab), for all indications of the...
Read More

Tags:

Previous Article

FDA Approves Osenvelt (denosumab-bmwo), a Biosimilar to Xgeva

Next Article

Target braces for first-quarter profit pressure due to tariffs, low demand

Related Posts

Imfinzi Approved in the US as First and Only Immunotherapy Regimen for Patients with Limited-Stage Small Cell Lung Cancer

Imfinzi Approved in the US as First and Only Immunother...

Feb 9, 2025  0

FDA Approves Ensacove (ensartinib) for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

FDA Approves Ensacove (ensartinib) for ALK-Positive Loc...

Feb 9, 2025  0

FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications

FDA Approves Opdivo Qvantig (nivolumab and hyaluronidas...

Feb 9, 2025  0